Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Oral Transmucosal Fentanyl (OVF) for Breakthrough Cancer Pain
jRCT2080220447Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fentanyl in breakthrough cancer pain (BTcP) and cancer pain, sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)cancer pain
Beyond the preview
Go deeper on jRCT2080220447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220447.